Researchers at Bristol University have created a lay summary for their research. The project will investigate the mechanisms of a new clinical drug combination currently in clinical trials for breast ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a key milestone in its ACESOT-1051 clinical trial, as the first patient with HPV-positive (HPV+) head and neck squamous cell ...

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and ...

A patient with HPV-positive head and neck squamous cell carcinoma was dosed in a phase 1 clinical trial evaluating APR-1051.

HPV driven cancers, including HPV+ HNSCC, are characterized by defects in the DDR pathway, making them potentially susceptible to WEE1 inhibition. HPV+ cancers are those where the underlying cause is ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 10.67%, which has investors questioning if this is right time ...

Azenosertib is a novel, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated as a monotherapy and combination clinical studies in ovarian cancer and additional tumor types.

Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 ...

H.C. Wainwright lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $19 from $22 and keeps a Buy rating on the shares. The firm ...